Vivy Tran

Vivy Tran

Auto-generated profile, based on publicly available information

Vivy Tran

Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
LCLucas Cusumano
Lucas Cusumano
VTVivy Tran
Vivy Tran
ATAileen Tlamsa
Aileen Tlamsa
PCPhilip Chung
Philip Chung
RGRobert Grossberg
Robert Grossberg
USUzma N. Sarwar
Uzma N. Sarwar
Medical tourism is increasingly popular for elective cosmetic surgical procedures. However, medical tourism has been accompanied by reports of post-surgical infections due to rapidly growing mycobacteria (RGM). The authors' experience working with patients with RGM infections who have returned to the USA after traveling abroad for cosmetic surgical procedures is described here. Patients who developed RGM infections after undergoing cosmetic surgeries abroad and who presented at the Montefiore Medical Center (Bronx, New York, USA) between August 2015 and June 2016 were identified. A review of patient medical records was performed. Four patients who presented with culture-proven RGM infections at the sites of recent cosmetic procedures were identified. All patients were treated with a combination of antibiotics and aggressive surgical treatment. This case series of RGM infections following recent cosmetic surgeries abroad highlights the risks of medical tourism. Close monitoring of affected patients by surgical and infectious disease specialties is necessary, as aggressive surgical debridement combined with appropriate antibiotic regimens is needed to achieve cure. Given the increasing reports of post-surgical RGM infections, consultants should have a low threshold for suspecting RGM, as rapid diagnosis may accelerate the initiation of targeted treatment and minimize morbidity.

27 November 2019 in Current Gastroenterology Reports
Verified
Journal Article
Closed access
PDF file
VTVivy Tran
Vivy Tran
BLBerkeley N. Limketkai
Berkeley N. Limketkai
JSJenny S. Sauk
Jenny S. Sauk

1 May 2019 in Clinical and Experimental Gastroenterology
Verified
Journal Article
Open access
PDF file
VTVivy Tran
Vivy Tran
RSRania M Shammas
Rania M Shammas
JSJenny S Sauk
Jenny S Sauk
DPDavid Padua
David Padua
The etiology of ulcerative colitis (UC) is complex and involves a host of genetic, epigenetic and environmental factors. Over the last thirty years, signaling pathways like the Janus kinase (JAK) signaling pathway have been implicated in its pathogenesis. Pharmacologic blockade of this pathway is available through several small molecule inhibitors, including tofacitinib. Tofacitinib is an orally administered pan-JAK inhibitor that was first approved by the Food and Drug Administration (FDA) for use in rheumatologic disorders such as rheumatoid arthritis and psoriatic arthritis. The FDA approved its use in moderate-to-severe active ulcerative colitis in 2018. The aim of this review will be to discuss the role of tofacitinib in ulcerative colitis. We will discuss the role of JAK-STAT signaling, clinical data available for tofacitinib, and the safety profile for this therapy. Tofacitinib’s place in the UC management algorithm is currently being debated. This effective oral therapy is poised to be a mainstay of UC therapeutics. This review will highlight the key clinical features and detail the UC experience to date.

1 February 2019 in Thrombosis Research
Verified
Journal Article
Closed access
AAAna Acuna-Villaorduna
Ana Acuna-Villaorduna
VTVivy Tran
Vivy Tran
JGJesus D. Gonzalez-Lugo
Jesus D. Gonzalez-Lugo
EAElham Azimi-Nekoo
Elham Azimi-Nekoo
HBHenny H. Billett
Henny H. Billett

1 January 2018 in ACG Case Reports Journal
Verified
Journal Article
Open access
VTVivy Tran
Vivy Tran
JPJennifer Phan
Jennifer Phan
BNBenjamin Nulsen
Benjamin Nulsen
LHLizhou Huang
Lizhou Huang
MKMarc Kaneshiro
Marc Kaneshiro
JSJenny S. Sauk
Jenny S. Sauk
Patients with inflammatory bowel disease (IBD) are at increased risk of developing Clostridium difficile infection (CDI). Fecal microbiota transplantation (FMT) is an effective therapy with a high success rate in preventing recurrent CDI. However, patients with IBD have decreased response to FMT for recurrent CDI, with several reports also suggesting potential IBD flare post-FMT. We present a case of mild ileocolonic Crohn's disease in a patient treated with FMT for recurrent CDI who subsequently developed severe steroid-refractory flare requiring surgical intervention 1 week post-FMT. Greater understanding of risk factors associated with post-FMT IBD flare is indicated.

1 May 2019 in Crohn's & Colitis 360
Verified
Journal Article
Open access
PDF file
AWAndrew T Weber
Andrew T Weber
NANimah Ather
Nimah Ather
VTVivy Tran
Vivy Tran
JSJenny Sauk
Jenny Sauk
CHChristina Ha
Christina Ha
Background and Aims: Patients with inflammatory bowel disease (IBD) require colonoscopy for diagnosis, disease activity assessment, and dysplasia surveillance. Few studies have evaluated anesthesia needs of IBD patients during procedures. This study aimed to examine sedation requirements of IBD patients undergoing colonoscopy. Methods: A retrospective cohort study of IBD and non-IBD patients presenting for colonoscopy between August 2015 and December 2016 was undertaken. Data collected included patient and procedure focused variables. Sedation was categorized as intravenous conscious sedation (IVCS) or monitored anesthesia care (MAC). Results: A total of: 522 consecutive colonoscopies (212 IBD, 310 non-IBD) between August 2015 and December 2016 met criteria for inclusion. In total, 323 cases utilized IVCS (56 IBD, 267 non-IBD) and 196 used MAC (155 IBD, 41 non-IBD). Compared with non-IBD patients (13.2%), more IBD patients (73.1%) required MAC (P < 0.01). For IVCS cases, IBD patients required more midazolam (5.73 mg versus non-IBD 4.31 mg; P <0.01) and opioid (IBD 157.59 µg fentanyl equivalents versus non-IBD 119.41 µg; P < 0.01). Diphenhydramine was more frequently added to IVCS for IBD cases (IBD 25.0% versus non-IBD 1.9%; P < 0.01). For MAC cases, propofol dosage was not significantly different between groups (IBD 355.64 mg versus non-IBD 317.104 mg; P = 0.29). IBD colonoscopies took longer (IBD 22.7 versus non-IBD 17.2 min; P < 0.01) and more patients had recent narcotic use (IBD 21.2% versus non-IBD 9.0%; P < 0.01). Conclusions: IBD patients required more IVCS, including greater diphenhydramine use with longer procedure times compared with non-IBD patients. These findings suggest MAC should be considered for IBD procedural sedation.